|Class||Name/Company||Approval Dates and Comments|
Approved by the FDA for the treatment of any progressive form of
fungal infection that fails to respond to conventional treatment. This
is in addition to its indication for aspergillosis.
Approved by the FDA on October 18, 1996 for the topical treatment
of interdigital tinea pedis (athleteís foot).
Approved by the FDA on December 6, 1996 for the “pulse treatment”
of onychomycosis of the fingernails. Available in 100 mg capsules.
The dose is 200 mg twice daily for the first week of each month for
two months. (The dose of 200 mg daily given for 12 weeks for
onychomycosis of the toenails is already established.)
Approved by the FDA on October 28, 1996 for the treatment of
severe recalcitrant psoriasis. Soriatane® will be available in 10 and
25 mg tablets.
Approved by the FDA for the treatment of recurrent herpes labialis.
This is the first topical antiviral cleared for this indication in
The FDA has approved valacyclovir for the new indication of treating
first episode genital herpes. This indication is also approved by the
Received marketing approval from the FDA early this month. It is
claimed to be the first such technology to be approved by the FDA
for use in installing hair plugs.
Permethrin was recently approved by the FDA for prophylactic use
during head lice epidemics. OTC.
(6 mg tablet)
Approved by the FDA on November 22, 1996 for the treament of
strongyloidiasis and onchocerciasis.
*Undergoing clinical trial for human scabies.